Nordic Bioscience

Treatment outcomes are deeply influenced by the tumor microenvironment (TME) where TGFβ (Transforming Growth Factor Beta) has emerged as a critical factor that can dictate the success—or failure—of therapeutic strategies. Understanding TGFβ activity could be a game-changer in personalizing cancer treatments. Our approach is designed to be implemented into clinical trials and research programs on TKI vs. IO, and to help explore the intersection of TGFβ biology and therapeutic resistance. 👉 Learn more: https://lnkd.in/dwVMUpiW Nicholas Willumsen Claus S. von Arenstorff Morten Asser Karsdal Daniel Gabor #TGFβ #Immunotherapy #TKI #Oncology #PrecisionMedicine #CancerResearch #Biomarkers

We’re wrapping up 2024 with our annual “Julehygge”! 🎄✨ For us, Julehygge is all about creating a cozy and festive atmosphere. It’s a time when our CEO, Morten, gives his year-end speech while we sip gløgg and indulge in way too much Christmas candy. 🍬 As always, no year-end speech from Morten would be complete without a classic Calvin and Hobbes reference and some heartfelt reflections on the year behind us and the one ahead. Today, we took a moment to celebrate the incredible people who make Nordic what it is. From the fearless innovators in R&D driving science forward, to the extraordinary efforts of our lab teams who ensure our partners get the best possible data—we’re proud to be doing a little better every day, all so we can make a difference for the patients in need. As Morten put it, we'll leave you with a quote from Abraham Lincoln: “The best way to predict the future is to create it.” Happy holidays! 🌟 Ps. The presents under the tree are full of biomarkers - just make sure everyone's levels are in check!

❗ Last chance to sign up for tomorrow's ECM webinar! This year's last webinar will examine pulmonary fibrosis in a translational context, with a focus on the mechanisms driving lung fibrosis and the role of machine learning in patient stratification, especially in COPD and other fibrotic pulmonary disorders. ➡️ Registration is closing: https://lnkd.in/dY4dw64f Naftali Kaminski Federica Genovese Line Egerod Lund Morten Asser Karsdal #webinar #COPD #Fibrosis #Pulmonary #IPF #Lung

📢 Only a week remains until this year's last ECM webinar: "Translational Science in Pulmonary Fibrosis: From patients to cells and back—increasing success in drug development"! On December 10, we will dive into the following topics: ✅ Investigating fibrosis mechanisms – what drives fibrosis in the lungs? ✅ Leveraging machine learning for patient stratification and advanced analytics – a COPD case study ✅ Utilizing translational biomarkers for drug development in fibrotic lung diseases ➡️ Sign up while seats last: https://lnkd.in/dydtYg52 Federica Genovese Diana Julie Leeming Morten Asser Karsdal Line Egerod Lund Martin Pehrsson, Ph.D Sarah Rønnow Daniel Gabor #webinar #COPD #liver #lung #pulmonary #IPF #translationalmedicine

Success does not simply occur—it is cultivated through curiosity, creativity, and the courage to pursue what once seemed unattainable. At Nordic Bioscience, we are fortunate to have employees who embody these qualities, transforming opportunities into achievements and dreams into reality. Today, we celebrate Charlotte Van Liedekerke for being nominated on the Forbes Belgium 30 under 30 List! This recognition underscores our purpose: to create a profound impact on science and healthcare. Charlotte’s success is but one example of the talent and determination within the Nordic team—a team that drives advancements that benefit patients worldwide. 📺 The full story: https://lnkd.in/dZnN-DiK Congratulations, Charlotte! 🎉 #Forbes #EmployeeRecognition #Excellence #LifeSciences

Speaker spotlight for the upcoming pulmonary webinar (Dec 10), co-hosted with The Extracellular Matrix Pharmacology Congress!   Three in-depth talks will examine pulmonary fibrosis in translational science, with a focus on the mechanisms driving lung fibrosis and the role of machine learning in patient stratification, especially in COPD and other fibrotic pulmonary disorders.   The presentations will cover the following topics and more: ✅ Investigating fibrosis mechanisms – what drives fibrosis in the lungs? ✅ Leveraging machine learning for patient stratification and advanced analytics – a COPD case study ✅ Utilizing translational biomarkers for drug development in fibrotic lung diseases   Federica Genovese Naftali Kaminski Line Egerod Lund Morten Asser KarsdalSarah Rønnow Martin Pehrsson, Ph.D Daniel Gabor   ➡️ Read more and sign up: https://lnkd.in/eHa7Nfkz   #webinar #COPD #liver #lung #pulmonary #IPF #translationalmedicine

In neurodegenerative diseases such as Parkinson’s Disease, the earliest changes in the brain are often molecular, involving the fragmentation and accumulation of specific proteins - processes that are key drivers of disease progression. One of these critical proteins is α-synuclein, a central player in Parkinson's pathology. Normally, α-synuclein functions in neuronal communication, but in Parkinson’s, it undergoes abnormal processing, including cleavage by enzymes like Calpain-1. This cleavage creates smaller, altered fragments of α-synuclein, which not only disrupt cellular functions but also have the unique ability to cross the blood-brain barrier and enter the bloodstream. These circulating fragments are valuable indicators of brain pathology and allow for a "window into the brain" from a blood sample, offering a less invasive way to study ongoing neurodegenerative processes.   α-Syn-C is a biomarker that detects brain-specific proteins in serum, reflecting the abnormal breakdown of α-Synuclein associated with Parkinson’s. α-Syn-C provides a convenient, accessible tool to monitor disease activity and therapeutic impact. ➡️ Read more about quantifying Parkinson's disease: https://lnkd.in/d3JTnTFU 📝 If you wish to learn how you can integrate α-SYN-C into your program, reach out to Signe Holm Nielsen, PhD! Morten Asser Karsdal Kim Henriksen Signe Hausgaard Larsen Daniel Gabor #Parkinsons #ParkinsonsDisease #neurology #DrugDevelopment

Back from #AHA2024 with a lot of new energy and knowledge! It was great to meet some old friends and new collaborators and to present our data on #collagen #biomarkers in #MI and #T2D as strong prognostic markers of outcome. It was also a great chance to visit Chicago for the first time and have some bonding time with my lovely colleagues Signe Hausgaard Larsen and Clara Fia Gøricke Laursen! Do reach out if you were unable to attend the talks and want to hear more!

❗Please note that we have changed the pulmonary webinar's date from Nov 28 to Dec 10! More information in the original post below. We look forward to co-hosting this educational session and hope to see many of you.